Az ifoszfamid szerepe az emlorák kezelésében

Magdolna Dank, Éva Pádi, Magdolna Csepreghy, E. Makó

Research output: Article

Abstract

Breast cancer is the most frequent solid tumor in women. Predictive and prognostic factors play an important role in the treatment of this cancer. We focused on high risk and heavily pre-treated metastatic breast cancer patients, trying to find the best combination of cytotoxic drugs with high efficacy and low toxicity. Ifosfamide is chemically related to nitrogen mustard and is a synthetic analogue of cyclophosphamide. Ifosfamide has a wide range of antitumor activity. Since ifosfamide as monotherapy has introduced significant tumor reduction in 1st line chemotherapy for advanced breast cancer, some studies started with high-dose continuous infusion of ifosfamide, or combined with paclitaxel or vinorelbine. Patients with poor prognosis primary breast cancer treated with high-dose chemotherapy supported by peripheral blood progenitor cell (PBSC) transplantation have lower risk for local relapse and longer diseasefree- survival. Ifosfamide working in the mobilization regimen has effective antitumor activity while mobilizing sufficient PBPCs in the majority of patients. In combination with other cytotoxics showed to be effective in high-dose protocols.

Original languageHungarian
Pages (from-to)69-73
Number of pages5
JournalMagyar Onkologia
Volume44
Issue number1
Publication statusPublished - 2000

Fingerprint

Ifosfamide
Breast Neoplasms
Therapeutics
Drug Therapy
Mechlorethamine
Neoplasms
Cell Transplantation
Drug Combinations
Paclitaxel
Cyclophosphamide
Blood Cells
Stem Cells
Recurrence
Survival

ASJC Scopus subject areas

  • Oncology

Cite this

Dank, M., Pádi, É., Csepreghy, M., & Makó, E. (2000). Az ifoszfamid szerepe az emlorák kezelésében. Magyar Onkologia, 44(1), 69-73.

Az ifoszfamid szerepe az emlorák kezelésében. / Dank, Magdolna; Pádi, Éva; Csepreghy, Magdolna; Makó, E.

In: Magyar Onkologia, Vol. 44, No. 1, 2000, p. 69-73.

Research output: Article

Dank, M, Pádi, É, Csepreghy, M & Makó, E 2000, 'Az ifoszfamid szerepe az emlorák kezelésében', Magyar Onkologia, vol. 44, no. 1, pp. 69-73.
Dank M, Pádi É, Csepreghy M, Makó E. Az ifoszfamid szerepe az emlorák kezelésében. Magyar Onkologia. 2000;44(1):69-73.
Dank, Magdolna ; Pádi, Éva ; Csepreghy, Magdolna ; Makó, E. / Az ifoszfamid szerepe az emlorák kezelésében. In: Magyar Onkologia. 2000 ; Vol. 44, No. 1. pp. 69-73.
@article{10a6e521c58a4dedaaa154b92eda7a7f,
title = "Az ifoszfamid szerepe az emlor{\'a}k kezel{\'e}s{\'e}ben",
abstract = "Breast cancer is the most frequent solid tumor in women. Predictive and prognostic factors play an important role in the treatment of this cancer. We focused on high risk and heavily pre-treated metastatic breast cancer patients, trying to find the best combination of cytotoxic drugs with high efficacy and low toxicity. Ifosfamide is chemically related to nitrogen mustard and is a synthetic analogue of cyclophosphamide. Ifosfamide has a wide range of antitumor activity. Since ifosfamide as monotherapy has introduced significant tumor reduction in 1st line chemotherapy for advanced breast cancer, some studies started with high-dose continuous infusion of ifosfamide, or combined with paclitaxel or vinorelbine. Patients with poor prognosis primary breast cancer treated with high-dose chemotherapy supported by peripheral blood progenitor cell (PBSC) transplantation have lower risk for local relapse and longer diseasefree- survival. Ifosfamide working in the mobilization regimen has effective antitumor activity while mobilizing sufficient PBPCs in the majority of patients. In combination with other cytotoxics showed to be effective in high-dose protocols.",
author = "Magdolna Dank and {\'E}va P{\'a}di and Magdolna Csepreghy and E. Mak{\'o}",
year = "2000",
language = "Hungarian",
volume = "44",
pages = "69--73",
journal = "Magyar Onkologia",
issn = "0025-0244",
publisher = "Akademiai Kiado",
number = "1",

}

TY - JOUR

T1 - Az ifoszfamid szerepe az emlorák kezelésében

AU - Dank, Magdolna

AU - Pádi, Éva

AU - Csepreghy, Magdolna

AU - Makó, E.

PY - 2000

Y1 - 2000

N2 - Breast cancer is the most frequent solid tumor in women. Predictive and prognostic factors play an important role in the treatment of this cancer. We focused on high risk and heavily pre-treated metastatic breast cancer patients, trying to find the best combination of cytotoxic drugs with high efficacy and low toxicity. Ifosfamide is chemically related to nitrogen mustard and is a synthetic analogue of cyclophosphamide. Ifosfamide has a wide range of antitumor activity. Since ifosfamide as monotherapy has introduced significant tumor reduction in 1st line chemotherapy for advanced breast cancer, some studies started with high-dose continuous infusion of ifosfamide, or combined with paclitaxel or vinorelbine. Patients with poor prognosis primary breast cancer treated with high-dose chemotherapy supported by peripheral blood progenitor cell (PBSC) transplantation have lower risk for local relapse and longer diseasefree- survival. Ifosfamide working in the mobilization regimen has effective antitumor activity while mobilizing sufficient PBPCs in the majority of patients. In combination with other cytotoxics showed to be effective in high-dose protocols.

AB - Breast cancer is the most frequent solid tumor in women. Predictive and prognostic factors play an important role in the treatment of this cancer. We focused on high risk and heavily pre-treated metastatic breast cancer patients, trying to find the best combination of cytotoxic drugs with high efficacy and low toxicity. Ifosfamide is chemically related to nitrogen mustard and is a synthetic analogue of cyclophosphamide. Ifosfamide has a wide range of antitumor activity. Since ifosfamide as monotherapy has introduced significant tumor reduction in 1st line chemotherapy for advanced breast cancer, some studies started with high-dose continuous infusion of ifosfamide, or combined with paclitaxel or vinorelbine. Patients with poor prognosis primary breast cancer treated with high-dose chemotherapy supported by peripheral blood progenitor cell (PBSC) transplantation have lower risk for local relapse and longer diseasefree- survival. Ifosfamide working in the mobilization regimen has effective antitumor activity while mobilizing sufficient PBPCs in the majority of patients. In combination with other cytotoxics showed to be effective in high-dose protocols.

UR - http://www.scopus.com/inward/record.url?scp=84875000591&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875000591&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84875000591

VL - 44

SP - 69

EP - 73

JO - Magyar Onkologia

JF - Magyar Onkologia

SN - 0025-0244

IS - 1

ER -